Jennifer Glaus1, Caroline L Vandeleur2, Aurélie M Lasserre3, Marie-Pierre F Strippoli3, Enrique Castelao3, Mehdi Gholam-Rezaee3, Gérard Waeber4, Jean-Michel Aubry5, Peter Vollenweider4, Martin Preisig3. 1. Psychiatric Epidemiology and Psychopathology Research Center, Lausanne University Hospital, Department of Psychiatry, Site de Cery, CH-1008 Prilly, Switzerland; Department of Mental Health and Psychiatry, Geneva University Hospital, Site de Belle-Idée, Chêne-Bourg, CH-1225 Geneva, Switzerland. 2. Psychiatric Epidemiology and Psychopathology Research Center, Lausanne University Hospital, Department of Psychiatry, Site de Cery, CH-1008 Prilly, Switzerland. Electronic address: Caroline.Vandeleur@chuv.ch. 3. Psychiatric Epidemiology and Psychopathology Research Center, Lausanne University Hospital, Department of Psychiatry, Site de Cery, CH-1008 Prilly, Switzerland. 4. Department of Internal Medicine, Lausanne University Hospital, Bâtiment hospitalier, Rue du Bugnon 46 CH-1011 Lausanne, Switzerland. 5. Department of Mental Health and Psychiatry, Geneva University Hospital, Site de Belle-Idée, Chêne-Bourg, CH-1225 Geneva, Switzerland.
Abstract
OBJECTIVE: Low-grade chronic inflammation is one potential mechanism underlying the well-established association between major depressive disorder (MDD) and increased cardiovascular morbidity. Both aspirin and statins have anti-inflammatory properties, which may contribute to their preventive effect on cardiovascular diseases. Previous studies on the potentially preventive effect of these drugs on depression have provided inconsistent results. The aim of the present paper was to assess the prospective association between regular aspirin or statin use and the incidence of MDD. METHOD: This prospective cohort study included 1631 subjects (43.6% women, mean age 51.7 years), randomly selected from the general population of an urban area. Subjects underwent a thorough physical evaluation as well as semi-structured interviews investigating DSM-IV mental disorders at baseline and follow-up (mean duration 5.2 years). Analyses were adjusted for a wide array of potential confounders. RESULTS: Our main finding was that regular aspirin or statin use at baseline did not reduce the incidence of MDD during follow-up, regardless of sex or age (hazard ratios, aspirin: 1.19; 95%CI, 0.68-2.08; and statins: 1.25; 95%CI, 0.73-2.14; respectively). LIMITATIONS: Our study is not a randomized clinical trial and could not adjust for all potential confounding factors, information on aspirin or statin use was collected only for the 6 months prior to the evaluations, and the sample was restricted to subjects between 35 and 66 years of age. CONCLUSION: Our data do not support a large scale preventive treatment of depression using aspirin or statins in subjects aged from 35 to 66 years from the community.
OBJECTIVE: Low-grade chronic inflammation is one potential mechanism underlying the well-established association between major depressive disorder (MDD) and increased cardiovascular morbidity. Both aspirin and statins have anti-inflammatory properties, which may contribute to their preventive effect on cardiovascular diseases. Previous studies on the potentially preventive effect of these drugs on depression have provided inconsistent results. The aim of the present paper was to assess the prospective association between regular aspirin or statin use and the incidence of MDD. METHOD: This prospective cohort study included 1631 subjects (43.6% women, mean age 51.7 years), randomly selected from the general population of an urban area. Subjects underwent a thorough physical evaluation as well as semi-structured interviews investigating DSM-IV mental disorders at baseline and follow-up (mean duration 5.2 years). Analyses were adjusted for a wide array of potential confounders. RESULTS: Our main finding was that regular aspirin or statin use at baseline did not reduce the incidence of MDD during follow-up, regardless of sex or age (hazard ratios, aspirin: 1.19; 95%CI, 0.68-2.08; and statins: 1.25; 95%CI, 0.73-2.14; respectively). LIMITATIONS: Our study is not a randomized clinical trial and could not adjust for all potential confounding factors, information on aspirin or statin use was collected only for the 6 months prior to the evaluations, and the sample was restricted to subjects between 35 and 66 years of age. CONCLUSION: Our data do not support a large scale preventive treatment of depression using aspirin or statins in subjects aged from 35 to 66 years from the community.
Authors: Michael Berk; Robyn L Woods; Mark R Nelson; Raj C Shah; Christopher M Reid; Elsdon Storey; Sharyn Fitzgerald; Jessica E Lockery; Rory Wolfe; Mohammadreza Mohebbi; Seetal Dodd; Anne M Murray; Nigel Stocks; Paul B Fitzgerald; Catherine Mazza; Bruno Agustini; John J McNeil Journal: JAMA Psychiatry Date: 2020-10-01 Impact factor: 21.596
Authors: Nicola Veronese; Ai Koyanagi; Brendon Stubbs; Marco Solmi; Michele Fornaro; Brisa S Fernandes; Christoph Mueller; Trevor Thompson; André F Carvalho; Stefania Maggi Journal: Int J Geriatr Psychiatry Date: 2017-08-06 Impact factor: 3.485
Authors: Bruno Agustini; Mohammadreza Mohebbi; Robyn L Woods; John J McNeil; Mark R Nelson; Raj C Shah; Anne M Murray; Michael E Ernst; Christopher M Reid; Andrew Tonkin; Jessica E Lockery; Michael Berk Journal: CNS Drugs Date: 2019-07 Impact factor: 5.749